Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.

Literature DB >> 16283539

Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.

Donald R Stanski¹, Malcolm Rowland, Lewis B Sheiner.

Abstract

This report highlights the main points emerging from a meeting sponsored on "Getting the Dose Right" in clinical development, jointly sponsored by the European Federation of Pharmaceutical Sciences and the European Center of Pharmaceutical Medicine, as part of the Workshop Series on Frontiers in Drug Development, in Basel, Switzerland on December 9-12, 2002.

Mesh：

Substances：

Year: 2005 PMID： 16283539 DOI： 10.1007/s10928-005-0010-x

Source DB: PubMed Journal: J Pharmacokinet Pharmacodyn ISSN： 1567-567X Impact factor: 2.745

10 in total

Review 1. Pharmacokinetic/pharmacodynamic modeling in drug development.

Authors: L B Sheiner; J L Steimer
Journal: Annu Rev Pharmacol Toxicol Date: 2000 Impact factor: 13.820

Review 2. Simulation of clinical trials.

Authors: N H Holford; H C Kimko; J P Monteleone; C C Peck
Journal: Annu Rev Pharmacol Toxicol Date: 2000 Impact factor: 13.820

3. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Authors: L J Lesko; M Rowland; C C Peck; T F Blaschke; D Breimer; H J de Jong; A Grahnen; J J Kuhlmann; B Stewart
Journal: Eur J Pharm Sci Date: 2000 Impact factor: 4.384

4. EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences.

Authors: G T Tucker; J B Houston; S M Huang
Journal: Eur J Pharm Sci Date: 2001-07 Impact factor: 4.384

5. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development.

Authors: Paul Rolan; Arthur J Atkinson; Lawrence J Lesko
Journal: Clin Pharmacol Ther Date: 2003-04 Impact factor: 6.875

6. Pharmaco-electroencephalography and pharmacokinetic-pharmacodynamic modeling in drug development: focus on preclinical steps.

Authors: M Danhof; S A G Visser
Journal: Methods Find Exp Clin Pharmacol Date: 2002

7. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.

Authors: James Cross; Howard Lee; Agnes Westelinck; Julie Nelson; Charles Grudzinskas; Carl Peck
Journal: Pharmacoepidemiol Drug Saf Date: 2002-09 Impact factor: 2.890

Review 8. Learning versus confirming in clinical drug development.

Authors: L B Sheiner
Journal: Clin Pharmacol Ther Date: 1997-03 Impact factor: 6.875

9. Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats.

Authors: S A G Visser; D R H Huntjens; P H van der Graaf; L A Peletier; M Danhof
Journal: J Pharmacol Exp Ther Date: 2003-09-15 Impact factor: 4.030

10. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke.

Authors: Michael Krams; Kennedy R Lees; Werner Hacke; Andrew P Grieve; Jean-Marc Orgogozo; Gary A Ford
Journal: Stroke Date: 2003-10-16 Impact factor: 7.914